Your browser doesn't support javascript.
loading
Multimodal profiling of chordoma immunity reveals distinct immune contextures.
van Oost, Siddh; Meijer, Debora M; Ijsselsteijn, Marieke E; Roelands, Jessica P; van den Akker, Brendy E M W; van der Breggen, Ruud; Briaire-de Bruijn, Inge H; van der Ploeg, Manon; Wijers-Koster, Pauline M; Polak, Samuel B; Peul, Wilco C; van der Wal, Robert J P; de Miranda, Noel F C C; Bovee, Judith V M G.
Affiliation
  • van Oost S; Department of Pathology, Leiden University Medical Center, Leiden, Netherlands.
  • Meijer DM; Leiden Center for Computational Oncology, Leiden University Medical Center, Leiden, Netherlands.
  • Ijsselsteijn ME; Department of Pathology, Leiden University Medical Center, Leiden, Netherlands.
  • Roelands JP; Leiden Center for Computational Oncology, Leiden University Medical Center, Leiden, Netherlands.
  • van den Akker BEMW; Department of Pathology, Leiden University Medical Center, Leiden, Netherlands.
  • van der Breggen R; Department of Pathology, Leiden University Medical Center, Leiden, Netherlands.
  • Briaire-de Bruijn IH; Department of Pathology, Leiden University Medical Center, Leiden, Netherlands.
  • van der Ploeg M; Department of Pathology, Leiden University Medical Center, Leiden, Netherlands.
  • Wijers-Koster PM; Department of Pathology, Leiden University Medical Center, Leiden, Netherlands.
  • Polak SB; Department of Pathology, Leiden University Medical Center, Leiden, Netherlands.
  • Peul WC; Department of Pathology, Leiden University Medical Center, Leiden, Netherlands.
  • van der Wal RJP; University Neurosurgical Center Holland, Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands.
  • de Miranda NFCC; University Neurosurgical Center Holland, Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands.
  • Bovee JVMG; Department of Orthopaedic Surgery, Leiden University Medical Center, Leiden, Netherlands.
J Immunother Cancer ; 12(1)2024 01 25.
Article in En | MEDLINE | ID: mdl-38272563
ABSTRACT

BACKGROUND:

Chordomas are rare cancers from the axial skeleton which present a challenging clinical management with limited treatment options due to their anatomical location. In recent years, a few clinical trials demonstrated that chordomas can respond to immunotherapy. However, an in-depth portrayal of chordoma immunity and its association with clinical parameters is still lacking.

METHODS:

We present a comprehensive characterization of immunological features of 76 chordomas through application of a multimodal approach. Transcriptomic profiling of 20 chordomas was performed to inform on the activity of immune-related genes through the immunologic constant of rejection (ICR) signature. Multidimensional immunophenotyping through imaging mass cytometry was applied to provide insights in the different immune contextures of 32 chordomas. T cell infiltration was further evaluated in all 76 patients by means of multispectral immunofluorescence and then associated with clinical parameters through univariate and multivariate Cox proportional hazard models as well as Kaplan-Meier estimates. Moreover, distinct expression patterns of human leukocyte antigen (HLA) class I were assessed by immunohistochemical staining in all 76 patients. Finally, clonal enrichment of the T cell receptor (TCR) was sought through profiling of the variable region of TCRB locus of 24 patients.

RESULTS:

Chordomas generally presented an immune "hot" microenvironment in comparison to other sarcomas, as indicated by the ICR transcriptional signature. We identified two distinct groups of chordomas based on T cell infiltration which were independent from clinical parameters. The highly infiltrated group was further characterized by high dendritic cell infiltration and the presence of multicellular immune aggregates in tumors, whereas low T cell infiltration was associated with lower overall cell densities of immune and stromal cells. Interestingly, patients with higher T cell infiltration displayed a more pronounced clonal enrichment of the TCR repertoire compared with those with low T cell counts. Furthermore, we observed that the majority of chordomas maintained HLA class I expression.

CONCLUSION:

Our findings shed light on the natural immunity against chordomas through the identification of distinct immune contextures. Understanding their immune landscape could guide the development and application of immunotherapies in a tailored manner, ultimately leading to an improved clinical outcome for patients with chordoma.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Chordoma Type of study: Prognostic_studies Limits: Humans Language: En Journal: J Immunother Cancer Year: 2024 Type: Article Affiliation country: Netherlands

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Chordoma Type of study: Prognostic_studies Limits: Humans Language: En Journal: J Immunother Cancer Year: 2024 Type: Article Affiliation country: Netherlands